CCT2 and cancer: Including fusions previously identified as cancer-related chimera (i.e. FRS2–MDM1, FRS2–PTPRR, CCT2–BEST3, RAB3IP–BEST3) of which both partner genes are overexpressed due to the amplification (Fig. 4d).